The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Aptevo Therapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst)
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Genentech; Ipsen; Janssen; Lilly; MedImmune
Other Relationship - Abbvie; Agios; Amgen; AMO Pharma; arGEN-X BVBA
 
Margitta Retz
No Relationships to Disclose
 
Peter Hammerer
Consulting or Advisory Role - Bayer; Janssen; Sanofi
 
Fernando Quevedo
No Relationships to Disclose
 
Peter C.C. Fong
Honoraria - AstraZeneca; Merck Sharp & Dohme
Consulting or Advisory Role - Merck Sharp & Dohme
Speakers' Bureau - Janssen
Travel, Accommodations, Expenses - Pfizer
 
William R. Berry
No Relationships to Disclose
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
 
Josep M. Piulats
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck Sharp & Dohme; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Janssen Oncology; Merck Sharp & Dohme; Pfizer/EMD Serono
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; Roche
 
Anthony Joshua
No Relationships to Disclose
 
Mark David Linch
Consulting or Advisory Role - BioNTech; Bristol-Myers Squibb; Janssen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck
 
Michael Kolinsky
Honoraria - Janssen
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen; Merck
Travel, Accommodations, Expenses - Novartis
 
Emanuela Romano
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Henry Jacob Conter
Honoraria - Bristol-Myers Squibb; Celgene; Merck; Novartis
Consulting or Advisory Role - Lilly; Roche Canada
 
Marinela Augustin
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; Novartis; Pfizer; PharmaMar; Roche
Travel, Accommodations, Expenses - Ipsen; Lilly; Novartis; PharmaMar
 
Haiyan Wu
Employment - MSD
Stock and Other Ownership Interests - Bayer (I); MSD (I)
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Christian Heinrich Poehlein
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; EMD Serono; Incyte; Janssen; Merck; QED Therapeutics; Tolmar
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen (Inst)